Cited by 381Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease

Ozben, Tomris, Ozben, Serkan·2019·Clinical Biochemistry

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. The pathological characteristics of AD include the deposition of amyloid beta (Aβ), neurofibrillary tangles, and neuronal loss. There is evidence showing the involvement of inflammation in AD, including activated microglia within and surrounding senile plaques. Epidemiological studies suggest the use of anti-inflammatory drugs to reduce incidence of AD. However, clinical trials with anti-inflammatory drugs have not been successful.

Integrity signals

Registry

Crossref · 10.1016/j.clinbiochem.2019.04.001

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In Alzheimer's disease, the increase in soluble Aβ oligomeric species, aggregated Aβ plaques and neurofibrillary tangles of hyperphosphorylated Tau proteins leads to activation of microglia and thus to neuroinflammation.

    “In AD, the increase in soluble Aβ oligomeric species, aggregated Aβ plaques and neurofibrillary tangles of hyperphosphorylated Tau proteins leads to activation of microglia and thus to neuroinflammation [79,139,140].”

    From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [139]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ozben, T., & Ozben, S.
Venue
Clinical Biochemistry
Publisher
Elsevier BV
Published
2019-10
Volume
72
Pages
87-89
ISSN
0009-9120 (ISSN-L)
OpenAlex
W2934170679
Cited by
381
References
21
Citations by year
2026: 21 · 2025: 66 · 2024: 75 · 2023: 88 · 2022: 64 · 2021: 38 · 2020: 26 · 2019: 3
FWCI
22.45
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, neuroinflammation, anti-inflammatory agents, amyloid-beta, neurofibrillary tangles, microglia, amyloid plaques, neurodegeneration, dementia, clinical trial failure
MeSH terms
Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Humans, Inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review